"Phthalazines" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
Below are MeSH descriptors whose meaning is more general than "Phthalazines".
Below are MeSH descriptors whose meaning is more specific than "Phthalazines".
This graph shows the total number of publications written about "Phthalazines" by people in Harvard Catalyst Profiles by year, and whether "Phthalazines" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2002 | 1 | 1 | 2 |
2003 | 0 | 2 | 2 |
2004 | 0 | 2 | 2 |
2005 | 0 | 1 | 1 |
2006 | 0 | 2 | 2 |
2007 | 2 | 0 | 2 |
2008 | 1 | 1 | 2 |
2009 | 2 | 1 | 3 |
2010 | 5 | 0 | 5 |
2011 | 1 | 3 | 4 |
2012 | 2 | 1 | 3 |
2013 | 1 | 5 | 6 |
2014 | 6 | 6 | 12 |
2015 | 2 | 2 | 4 |
2016 | 7 | 4 | 11 |
2017 | 11 | 1 | 12 |
2018 | 7 | 3 | 10 |
2019 | 5 | 10 | 15 |
2020 | 6 | 9 | 15 |
2021 | 7 | 11 | 18 |
2022 | 1 | 13 | 14 |
2023 | 0 | 5 | 5 |
2024 | 1 | 2 | 3 |
Below are the most recent publications written about "Phthalazines" by people in Profiles.
-
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer. Clin Cancer Res. 2024 Apr 01; 30(7):1240-1247.
-
Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer. J Clin Oncol. 2024 Apr 10; 42(11):1288-1300.
-
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clin Cancer Res. 2024 01 05; 30(1):50-62.
-
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma. Br J Cancer. 2024 02; 130(3):476-482.
-
Phase II Study of Olaparib and Temozolomide for Advanced Uterine Leiomyosarcoma (NCI Protocol 10250). J Clin Oncol. 2023 09 01; 41(25):4154-4163.
-
Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies. Oncologist. 2023 07 05; 28(7):565-574.
-
Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: Subgroup analyses from the phase III OlympiAD trial. Int J Cancer. 2023 08 15; 153(4):803-814.
-
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Eur J Cancer. 2023 05; 184:39-47.
-
Randomized Trial of Olaparib With or Without Cediranib for Metastatic Castration-Resistant Prostate Cancer: The Results From National Cancer Institute 9984. J Clin Oncol. 2023 02 01; 41(4):871-880.
-
PARP-inhibition reprograms macrophages toward an anti-tumor phenotype. Cell Rep. 2022 10 11; 41(2):111462.